Ramy Yaacoub
HS Assistant Clinical Professor, Urology
School of Medicine
School of Medicine
M.D., Mansoura University, Egypt, 2006, Urology
University of California, Irvine
333 City Blvd West
Suite 2100
Orange, CA 92868
333 City Blvd West
Suite 2100
Orange, CA 92868
Research Abstract
1. Prognostic role of mTOR pathway biomarkers in bladder cancer
2. Creation of Validated Prognostic Panel of Biomarkers for Squamous Cell Carcinoma of the bladder
3. Role of PD-L1 and immune check point pathway in different histopathological types of bladder cancer
4. Bladder cancer biomarkers: FOXA1 pathway markers
5. Gene sequencing for Schistosoma associated squamous cell carcinoma of the bladder
6. Clinical Validation of A Urine-Based Assay With Genomic and Epigenomic Markers for Predicting Recurrence during Surveillance For Non-Muscle Invasive Bladder Cancer: Genomic Health
7. Bond: An open-label, single-arm, phase II, multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with non-muscle invasive bladder carcinoma who have failed BCG therapy and refused cystectomy
8. SPI-EOQ-13-305: A multicernter, Multi- Arm, Randomized, Multi-Dose, Placebo-Controlled Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin) as a surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing Transurethral Resecion for Non-Muscle Invasive Bladder Cancer
9. A Phase Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma Epidemiological trends of bladder cancer in California
10. Time Trends in Metabolic Diagnoses and Epidemiological Characteristics of Stone Formers
11. Geographical differences in Metabolic Diagnoses of Stone Formers
12. A survey of antimicrobial use prior to endourological surgery for urolithiasis
13. Phase I trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
14. Multicenter Prospective Randomized Comparison of Fluoroscopy versus Ultrasound Guided Access for Percutaneous NephrolithotomyEvaluation Of Skin-To-Tumor Distance As A Predictor Of Tumor Recurrence Following Percutaneous Cryoablation Of Renal Cortical Neoplasms Prospective, Randomized Comparison of Conventional and Triple Bolus CT Urography
15. Protocols in the Management of HematuriaA MultiCenter, Retrospective Comparison of Accuracy and Quality of Upper Urinary Tract Biopsy DevicesPrevalence of Protective Shielding Utilization for Radiation Dose Reduction in Adult Patients Undergoing Computed Tomography
16. Three-Dimensional Printed Kidney Models With Extensive Urolithiasis: A Novel Educational Tool For Planning Percutaneous Nephrolithotomy Comparisons Between Different Techniques Of Percutaneous Renal Biopsy For Small Renal Cortical Neoplasms Percutaneous nephrolithotomy after recent urolithiasis related sepsis: What should patients expect? Answers from a matched pair analysis
17. A Phase II Clnical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
2. Creation of Validated Prognostic Panel of Biomarkers for Squamous Cell Carcinoma of the bladder
3. Role of PD-L1 and immune check point pathway in different histopathological types of bladder cancer
4. Bladder cancer biomarkers: FOXA1 pathway markers
5. Gene sequencing for Schistosoma associated squamous cell carcinoma of the bladder
6. Clinical Validation of A Urine-Based Assay With Genomic and Epigenomic Markers for Predicting Recurrence during Surveillance For Non-Muscle Invasive Bladder Cancer: Genomic Health
7. Bond: An open-label, single-arm, phase II, multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with non-muscle invasive bladder carcinoma who have failed BCG therapy and refused cystectomy
8. SPI-EOQ-13-305: A multicernter, Multi- Arm, Randomized, Multi-Dose, Placebo-Controlled Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin) as a surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing Transurethral Resecion for Non-Muscle Invasive Bladder Cancer
9. A Phase Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma Epidemiological trends of bladder cancer in California
10. Time Trends in Metabolic Diagnoses and Epidemiological Characteristics of Stone Formers
11. Geographical differences in Metabolic Diagnoses of Stone Formers
12. A survey of antimicrobial use prior to endourological surgery for urolithiasis
13. Phase I trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
14. Multicenter Prospective Randomized Comparison of Fluoroscopy versus Ultrasound Guided Access for Percutaneous NephrolithotomyEvaluation Of Skin-To-Tumor Distance As A Predictor Of Tumor Recurrence Following Percutaneous Cryoablation Of Renal Cortical Neoplasms Prospective, Randomized Comparison of Conventional and Triple Bolus CT Urography
15. Protocols in the Management of HematuriaA MultiCenter, Retrospective Comparison of Accuracy and Quality of Upper Urinary Tract Biopsy DevicesPrevalence of Protective Shielding Utilization for Radiation Dose Reduction in Adult Patients Undergoing Computed Tomography
16. Three-Dimensional Printed Kidney Models With Extensive Urolithiasis: A Novel Educational Tool For Planning Percutaneous Nephrolithotomy Comparisons Between Different Techniques Of Percutaneous Renal Biopsy For Small Renal Cortical Neoplasms Percutaneous nephrolithotomy after recent urolithiasis related sepsis: What should patients expect? Answers from a matched pair analysis
17. A Phase II Clnical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
Publications
79. Jeremy W Martin; Francis A. Jefferson; Melissa Huang; John M Sung; Jenny Chang; Keyhan Piranviseh; Argyrios Ziogas; Hoda Anton-Culver; Ramy F Youssef. A California Cancer Registry
78. John M Sung; Jeremy W Martin; Francis A Jefferson; Daniel A Sidhom; Keyhan Piranviseh; Melissa Huang; Nobel Nguyen; Jenny Chang; Argyrios Ziogas; Hoda Anton-Culver; Ramy F Youssef. Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry. (CGUC MS# CGUC-D-19-00133R1)
77. Owyong M, Lotan Y, Kapur P, Panwar V, McKenzie T, Lee TK, Zi X, Martin JW, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. Urol Oncol. 2019 Mar 22. pii: S1078-1439(19)30093-6. doi: 10.1016/j.urolonc.2019.02.017. [Epub ahead of print] PMID: 30910351
76. Khajeh NR, Khoyilar C, Wu Y, Spradling K, Zi X, Youssef RF. Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts. Mini Rev Med Chem. 2018;18(13):1143-1150. doi: 10.2174/1389557516666160315114132. Review.PMID:26975668
75. 6: Iqbal MW, Shin RH, Youssef RF, Kaplan AG, Cabrera FJ, Hanna J, Scales CD Jr,
Ferrandino MN, Preminger GM, Lipkin ME. Should metabolic evaluation be performed
in patients with struvite stones? Urolithiasis. 2017 Apr;45(2):185-192. doi:
10.1007/s00240-016-0893-6. Epub 2016 May 30. PubMed PMID: 27240693.
Ferrandino MN, Preminger GM, Lipkin ME. Should metabolic evaluation be performed
in patients with struvite stones? Urolithiasis. 2017 Apr;45(2):185-192. doi:
10.1007/s00240-016-0893-6. Epub 2016 May 30. PubMed PMID: 27240693.
74. Degener S, Mata DA, Youssef R, Gödde D, Tandogdu Z, Roth S, von Rundstedt FC.
A Review of Molecular Predictors of Response to Neoadjuvant Chemotherapy in
Muscle-invasive Bladder Cancer. Mini Rev Med Chem. 2018;18(13):1133-1142. doi:
10.2174/1389557516666160315114522. Review. PubMed PMID: 26975667.
A Review of Molecular Predictors of Response to Neoadjuvant Chemotherapy in
Muscle-invasive Bladder Cancer. Mini Rev Med Chem. 2018;18(13):1133-1142. doi:
10.2174/1389557516666160315114522. Review. PubMed PMID: 26975667.
73. Carlos EC, Youssef RF, Kaplan AG, Wollin DA, Winship BB, Eisner BH, Sur RL, Preminger GM, Lipkin ME. Antibiotic Utilization Before Endourological Surgery for Urolithiasis: Endourological Society Survey Results J Endourol. 2018 Sep 21. doi: 10.1089/end.2018.0494. [Epub ahead of print] PMID: 30113226
72. Martin JW, Vernez SL, Lotan Y, Abdelhalim A, Dutta R, Shokeir A, Abol-Enein H, Mosbah A, Ghoneim M, Youssef RF. Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort., World J Urol. 2018 May 14. doi: 10.1007/s00345-018-2331-6. [Epub ahead of print]
71. Vernez SL, Okhunov Z, Kaler K, Youssef RF, Dutta R, Palvanov A, Shah P, Osann K, Siegel DN, Lobko I, Kavoussi L, Clayman RV, Landman J. Skin-to-tumor Distance Predicts Treatment Failure of T1a Renal Cell Carcinoma Following Percutaneous Cryoablation. Urology. 2017 Jun 23. pii: S0090-4295(17)30647-7. doi: 10.1016/j.urology.2017.06.026 PMID: 28652159
1. el-Assmy A, el-Nahas AR, Youssef RF, el-Hefnawy AS, Sheir KZ: Does degree of hydronephrosis affect success of extracorporeal shock wave lithotripsy for distal ureteral stones? Urology 2007, 69(3):431-435.
2. El-Assmy A, El-Nahas AR, Youssef RF, El-Hefnawy AS, Sheir KZ: Impact of the degree of hydronephrosis on the efficacy of in situ extracorporeal shock-wave lithotripsy for proximal ureteral calculi. Scandinavian journal of urology and nephrology 2007, 41(3):208-213.
3. El-Assmy A, Abo-Elghar ME, El-Nahas AR, Youssef RF, El-Diasty T, Sheir KZ: Anatomic predictors of formation of lower caliceal calculi: is it the time for three-dimensional computed tomography urography? Journal of endourology 2008, 22(9):2175-2179.
4. el-Assmy A, el-Nahas AR, Hekal IA, Badran M, Youssef RF, Sheir KZ: Long-term effects of extracorporeal shock wave lithotripsy on renal function: our experience with 156 patients with solitary kidney. The Journal of urology 2008, 179(6):2229-2232.
5. El-Nahas AR, El-Tabey NA, Eraky I, Shoma AM, El-Hefnawy AS, El-Assmy AM, Soliman S, Youssef RF, El-Kenawy MR, Shokeir AA et al: Semirigid ureteroscopy for ureteral stones: a multivariate analysis of unfavorable results. The Journal of urology 2009, 181(3):1158-1162.
6. Youssef RF, El-Nahas AR, El-Assmy AM, El-Tabey NA, El-Hefnawy AS, Eraky I, El-Kenawy MR, El-Kappany HA, Sheir KZ: Shock wave lithotripsy versus semirigid ureteroscopy for proximal ureteral calculi (<20 mm): a comparative matched-pair study. Urology 2009, 73(6):1184-1187.
7. Youssef RF, Mitra AP, Bartsch G, Jr., Jones PA, Skinner DG, Cote RJ: Molecular targets and targeted therapies in bladder cancer management. World journal of urology 2009, 27(1):9-20.
8. Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M et al: Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. The Journal of urology 2010, 184(2):453-458.
9. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y: Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. The Journal of urology 2010, 183(5):1744-1750.
10. Cost NG, Delacroix SE, Jr., Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J et al: The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. European urology 2011, 59(6):912-918.
11. Gurbuz C, Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD et al: The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. Journal of endourology 2011, 25(5):775-779.
12. Kapur P, Lotan Y, King E, Kabbani W, Mitra AP, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF: Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers. American journal of clinical pathology 2011, 135(6):822-830.
13. Youssef R, Kapur P, Kabbani W, Shariat SF, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. BJU international 2011, 108(1):31-37.
14. Youssef RF: Prostate sparing cystectomy: A procedure with limited indications. Arab journal of urology 2011, 9(2):113-114.
15. Youssef RF, Lotan Y: Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. TheScientificWorldJournal 2011, 11:369-381.
16. Youssef RF, Margulis V: Editorial comment. The Journal of urology 2011, 186(2):415; author reply 415-416.
17. Youssef RF, Raj GV: Lymphadenectomy in management of invasive bladder cancer. International journal of surgical oncology 2011, 2011:758189.
18. Youssef RF, Shariat SF, Kapur P, Kabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M et al: Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. Human pathology 2011, 42(3):347-355.
19. Youssef RF, Shariat SF, Kapur P, Kabbani W, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder. The Journal of urology 2011, 185(3):1112-1117.
20. Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M et al: Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU international 2011, 108(8):1286-1291.
21. Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V: Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. Urology 2011, 77(4):861-866.
22. Adibi M, Youssef R, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V: Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. International journal of urology : official journal of the Japanese Urological Association 2012, 19(12):1060-1066.
23. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, Shariat SF, Lotan Y et al: Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. European urology 2012, 62(1):e27-29.
24. Best SL, Park SK, Youssef RF, Olweny EO, Tan YK, Trimmer C, Cadeddu JA: Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. The Journal of urology 2012, 187(4):1183-1189.
25. El-Nahas AR, Ibrahim HM, Youssef RF, Sheir KZ: Flexible ureterorenoscopy versus extracorporeal shock wave lithotripsy for treatment of lower pole stones of 10-20 mm. BJU international 2012, 110(6):898-902.
26. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, Shariat SF, Tangen CM, Thompson IM, Jr., Klein EA: Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. The Journal of urology 2012, 187(6):2005-2010.
27. Rippel CA, Nikkel L, Lin YK, Danawala Z, Olorunnisomo V, Youssef RF, Pearle MS, Lotan Y, Raman JD: Residual fragments following ureteroscopic lithotripsy: incidence and predictors on postoperative computerized tomography. The Journal of urology 2012, 188(6):2246-2251.
28. Youssef R, Kapur P, Shariat SF, Arendt T, Kabbani W, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y: Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. BJU international 2012, 110(7):961-966.
29. Youssef RF, Cost NG, Darwish OM, Margulis V: Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway. Arab journal of urology 2012, 10(2):110-117.
30. Youssef RF, Margulis V: Editorial comment. The Journal of urology 2012, 187(5):1711-1712.
31. Youssef RF, Margulis V: Urothelial carcinoma: Endoscopy to predict outcomes in upper tract urothelial cancer. Nature reviews Urology 2012, 9(5):242-243.
32. Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y: Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urologic oncology 2012, 30(3):273-277.
33. Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V: Preoperative pulmonary embolism does not predict poor postoperative outcomes in patients with renal cell carcinoma and venous thrombus. The Journal of urology 2013, 190(2):452-457.
34. Darwish OM, Kapur P, Youssef RF, Bagrodia A, Belsante M, Alhalabi F, Sagalowsky AI, Lotan Y, Margulis V: Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 2013, 81(3):581-586.
35. Ellis CL, Chang AG, Cimino-Mathews A, Argani P, Youssef RF, Kapur P, Montgomery EA, Epstein JI: GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. The American journal of surgical pathology 2013, 37(11):1756-1760.
36. Gayed BA, Youssef RF, Bagrodia A, Kapur P, Darwish OM, Krabbe LM, Sagalowsky A, Lotan Y, Margulis V: Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma. The Journal of urology 2013, 190(5):1662-1667.
37. Youssef RF, Lotan Y, Sagalowsky AI, Shariat SF, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F et al: Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy? International braz j urol : official journal of the Brazilian Society of Urology 2013, 39(5):614-621.
38. Youssef RF, Shariat SF, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F et al: Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy. Urologic oncology 2013, 31(5):676-681.
39. Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, Lotan Y, Margulis V: Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival. Urologic oncology 2014, 32(1):30.e23-38.
40. Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, Bhat D, Lotan Y: What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urologic oncology 2014, 32(2):128-134.
41. Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, Lotan Y, Margulis V: Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU international 2014, 113(4):668-673.
42. Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M et al: Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. The Journal of urology 2014, 191(1):28-34.
43. Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF, Bolenz C, Sagalowsky AI, Raj GV, Shariat SF et al: Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology? The Journal of urology 2014, 191(4):926-931.
44. Kuntz NJ, Neisius A, Astroza GM, Tsivian M, Iqbal MW, Youssef R, Ferrandino MN, Preminger GM, Lipkin ME: Does body mass index impact the outcomes of tubeless percutaneous nephrolithotomy? BJU international 2014, 114(3):404-411.
45. Rausch S, Lotan Y, Youssef RF: Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: a contemporary review with focus on nonbilharzial squamous cell carcinoma. Urologic oncology 2014, 32(1):32.e11-36.
46. Youssef RF, Neisius A, Goldsmith ZG, Ghaffar M, Tsivian M, Shin RH, Cabrera F, Ferrandino MN, Scales CD, Preminger GM et al: Clinical outcomes after ureteroscopic lithotripsy in patients who initially presented with urosepsis: matched pair comparison with elective ureteroscopy. Journal of endourology 2014, 28(12):1439-1443.
47. Gayed BA, Bagrodia A, Gaitonde M, Krabbe LM, Meissner M, Kapur P, Youssef RF, Sagalowsky A, Lotan Y, Margulis V: Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results. Urologic oncology 2015, 33(1):18.e21-16.
48. Singla N, Gayed BA, Bagrodia A, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O et al: Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. Urologic oncology 2015, 33(6):268.e261-267.
49. Spradling K, Khoyilar C, Abedi G, Okhunov Z, Wikenheiser J, Yoon R, Huang J, Youssef RF, Ghoniem G, Landman J: Redefining the Autonomic Nerve Distribution of the Bladder Using 3-Dimensional Image Reconstruction. The Journal of urology 2015, 194(6):1661-1667.
50. Spradling K, Uribe B, Okhunov Z, Hofmann M, Del Junco M, Hwang C, Gruber C, Youssef RF, Landman J: Evaluation of Ignition and Burn Risk Associated with Contemporary Fiberoptic and Distal Sensor Endoscopic Technology. Journal of endourology 2015, 29(9):1076-1082.
51. Youssef RF, Kapur P, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y: Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target. Urologic oncology 2015, 33(3):111.e111-117.
52. Youssef RF, Krabbe LM, Shariat SF, Lotan Y, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F et al: TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World journal of urology 2015, 33(12):1965-1972.
53. Youssef RF, Spradling K, Yoon R, Dolan B, Chamberlin J, Okhunov Z, Clayman R, Landman J: Applications of three-dimensional printing technology in urological practice. BJU international 2015, 116(5):697-702.
54. Youssef RF, von Rundstedt FC, Kapur P, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y: Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma. The Journal of urology 2015, 193(2):451-456.
55. Cabrera FJ, Kaplan AG, Youssef RF, Tsivian M, Shin RH, Scales CD, Preminger GM, Lipkin ME: Digital Tomosynthesis: A Viable Alternative to Noncontrast Computed Tomography for the Follow-Up of Nephrolithiasis? Journal of endourology 2016, 30(4):366-370.
56. Degener S, Mata DA, Youssef R, Godde D, Tandogdu Z, Roth S, von Rundstedt FC: A review of molecular predictors of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Mini reviews in medicinal chemistry 2016.
57. Dutta R, Abdelhalim A, Martin JW, Vernez SL, Faltas B, Lotan Y, Youssef RF: Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urologic oncology 2016.
58. Dutta R, Okhunov Z, Vernez SL, Kaler K, Gulati AT, Youssef RF, Nelson K, Lotan Y, Landman J: Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses. Journal of endourology 2016, 30 Suppl 1:S28-33.
59. Gayed BA, Youssef R, Darwish O, Kapur P, Bagrodia A, Brugarolas J, Raj G, DiMaio JM, Sagalowsky A, Margulis V: Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned. BMC urology 2016, 16(1):43.
60. Iqbal MW, Shin RH, Youssef RF, Kaplan AG, Cabrera FJ, Hanna J, Scales CD, Jr., Ferrandino MN, Preminger GM, Lipkin ME: Should metabolic evaluation be performed in patients with struvite stones? Urolithiasis 2016.
61. Iqbal MW, Youssef RF, Neisius A, Kuntz N, Hanna J, Ferrandino MN, Preminger GM, Lipkin ME: Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome. Journal of endourology 2016, 30(7):771-777.
62. Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, Pollak M et al: High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with approximately 240-Fold Higher Drug Concentration in Urine than Serum. Molecular cancer therapeutics 2016, 15(3):430-438.
63. Martin JW, Carballido EM, Ahmed A, Farhan B, Dutta R, Smith C, Youssef RF: Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab journal of urology 2016, 14(3):183-191.
64. Okhunov Z, Chamberlin J, Moreira DM, George A, Babaian K, Shah P, Youssef R, Kaler KS, Lobko, II, Kavoussi L et al: Salvage Percutaneous Cryoablation for Locally Recurrent Renal-Cell Carcinoma After Primary Cryoablation. Journal of endourology 2016, 30(6):632-637.
65. Okhunov Z, Moreira DM, Del Junco M, Abedi G, Lobko I, Kaler K, Nguyen ND, Youssef RF, Uchio E, Kavoussi LR et al: Predictors of Complications after Percutaneous Image-Guided Renal Cryoablation for T1a Renal Cortical Neoplasms. Journal of endourology 2016.
66. Shin RH, Cabrera FJ, Nguyen G, Wang C, Youssef RF, Scales CD, Ferrandino MN, Preminger GM, Yoshizumi TT, Lipkin ME: Radiation Dosimetry for Ureteroscopy Patients: A Phantom Study Comparing the Standard and Obese Patient Models. Journal of endourology 2016, 30(1):57-62.
67. Spradling K, Lotan Y, Shokeir A, Abol-Enein H, Mosbah A, Morgan JB, Ghoneim M, Youssef RF: Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder. Urologic oncology 2016, 34(9):417.e411-418.
68. Spradling K, Vernez SL, Khoyliar C, Morgan JB, Okhunov Z, Preminger GM, Lipkin ME, Landman J, Youssef RF: Prevalence of Hyperoxaluria in Urinary Stone Formers: Chronological and Geographical Trends and a Literature Review. Journal of endourology 2016, 30(4):469-475.
69. Spradling K, Youssef RF: Controversies Related to Diabetes and Risk of Bladder Cancer. Mini reviews in medicinal chemistry 2016.
70. Haddad, A. Q., Luo, J.-H., Krabbe, L.-M., Darwish, O., Gayed, B., Youssef, R., Kapur, P., Rakheja, D., Lotan, Y., Sagalowsky, A. and Margulis, V. (2017), Prognostic Value of Tissue Based Biomarker Signature in Clear Cell Renal Cell Carcinoma. BJU Int. Accepted Author Manuscript. doi:10.1111/bju.13776
2. El-Assmy A, El-Nahas AR, Youssef RF, El-Hefnawy AS, Sheir KZ: Impact of the degree of hydronephrosis on the efficacy of in situ extracorporeal shock-wave lithotripsy for proximal ureteral calculi. Scandinavian journal of urology and nephrology 2007, 41(3):208-213.
3. El-Assmy A, Abo-Elghar ME, El-Nahas AR, Youssef RF, El-Diasty T, Sheir KZ: Anatomic predictors of formation of lower caliceal calculi: is it the time for three-dimensional computed tomography urography? Journal of endourology 2008, 22(9):2175-2179.
4. el-Assmy A, el-Nahas AR, Hekal IA, Badran M, Youssef RF, Sheir KZ: Long-term effects of extracorporeal shock wave lithotripsy on renal function: our experience with 156 patients with solitary kidney. The Journal of urology 2008, 179(6):2229-2232.
5. El-Nahas AR, El-Tabey NA, Eraky I, Shoma AM, El-Hefnawy AS, El-Assmy AM, Soliman S, Youssef RF, El-Kenawy MR, Shokeir AA et al: Semirigid ureteroscopy for ureteral stones: a multivariate analysis of unfavorable results. The Journal of urology 2009, 181(3):1158-1162.
6. Youssef RF, El-Nahas AR, El-Assmy AM, El-Tabey NA, El-Hefnawy AS, Eraky I, El-Kenawy MR, El-Kappany HA, Sheir KZ: Shock wave lithotripsy versus semirigid ureteroscopy for proximal ureteral calculi (<20 mm): a comparative matched-pair study. Urology 2009, 73(6):1184-1187.
7. Youssef RF, Mitra AP, Bartsch G, Jr., Jones PA, Skinner DG, Cote RJ: Molecular targets and targeted therapies in bladder cancer management. World journal of urology 2009, 27(1):9-20.
8. Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M et al: Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. The Journal of urology 2010, 184(2):453-458.
9. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y: Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. The Journal of urology 2010, 183(5):1744-1750.
10. Cost NG, Delacroix SE, Jr., Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J et al: The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. European urology 2011, 59(6):912-918.
11. Gurbuz C, Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD et al: The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. Journal of endourology 2011, 25(5):775-779.
12. Kapur P, Lotan Y, King E, Kabbani W, Mitra AP, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF: Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers. American journal of clinical pathology 2011, 135(6):822-830.
13. Youssef R, Kapur P, Kabbani W, Shariat SF, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. BJU international 2011, 108(1):31-37.
14. Youssef RF: Prostate sparing cystectomy: A procedure with limited indications. Arab journal of urology 2011, 9(2):113-114.
15. Youssef RF, Lotan Y: Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. TheScientificWorldJournal 2011, 11:369-381.
16. Youssef RF, Margulis V: Editorial comment. The Journal of urology 2011, 186(2):415; author reply 415-416.
17. Youssef RF, Raj GV: Lymphadenectomy in management of invasive bladder cancer. International journal of surgical oncology 2011, 2011:758189.
18. Youssef RF, Shariat SF, Kapur P, Kabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M et al: Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. Human pathology 2011, 42(3):347-355.
19. Youssef RF, Shariat SF, Kapur P, Kabbani W, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder. The Journal of urology 2011, 185(3):1112-1117.
20. Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M et al: Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU international 2011, 108(8):1286-1291.
21. Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V: Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. Urology 2011, 77(4):861-866.
22. Adibi M, Youssef R, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V: Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. International journal of urology : official journal of the Japanese Urological Association 2012, 19(12):1060-1066.
23. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, Shariat SF, Lotan Y et al: Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. European urology 2012, 62(1):e27-29.
24. Best SL, Park SK, Youssef RF, Olweny EO, Tan YK, Trimmer C, Cadeddu JA: Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. The Journal of urology 2012, 187(4):1183-1189.
25. El-Nahas AR, Ibrahim HM, Youssef RF, Sheir KZ: Flexible ureterorenoscopy versus extracorporeal shock wave lithotripsy for treatment of lower pole stones of 10-20 mm. BJU international 2012, 110(6):898-902.
26. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, Shariat SF, Tangen CM, Thompson IM, Jr., Klein EA: Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. The Journal of urology 2012, 187(6):2005-2010.
27. Rippel CA, Nikkel L, Lin YK, Danawala Z, Olorunnisomo V, Youssef RF, Pearle MS, Lotan Y, Raman JD: Residual fragments following ureteroscopic lithotripsy: incidence and predictors on postoperative computerized tomography. The Journal of urology 2012, 188(6):2246-2251.
28. Youssef R, Kapur P, Shariat SF, Arendt T, Kabbani W, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y: Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. BJU international 2012, 110(7):961-966.
29. Youssef RF, Cost NG, Darwish OM, Margulis V: Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway. Arab journal of urology 2012, 10(2):110-117.
30. Youssef RF, Margulis V: Editorial comment. The Journal of urology 2012, 187(5):1711-1712.
31. Youssef RF, Margulis V: Urothelial carcinoma: Endoscopy to predict outcomes in upper tract urothelial cancer. Nature reviews Urology 2012, 9(5):242-243.
32. Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y: Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urologic oncology 2012, 30(3):273-277.
33. Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V: Preoperative pulmonary embolism does not predict poor postoperative outcomes in patients with renal cell carcinoma and venous thrombus. The Journal of urology 2013, 190(2):452-457.
34. Darwish OM, Kapur P, Youssef RF, Bagrodia A, Belsante M, Alhalabi F, Sagalowsky AI, Lotan Y, Margulis V: Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 2013, 81(3):581-586.
35. Ellis CL, Chang AG, Cimino-Mathews A, Argani P, Youssef RF, Kapur P, Montgomery EA, Epstein JI: GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. The American journal of surgical pathology 2013, 37(11):1756-1760.
36. Gayed BA, Youssef RF, Bagrodia A, Kapur P, Darwish OM, Krabbe LM, Sagalowsky A, Lotan Y, Margulis V: Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma. The Journal of urology 2013, 190(5):1662-1667.
37. Youssef RF, Lotan Y, Sagalowsky AI, Shariat SF, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F et al: Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy? International braz j urol : official journal of the Brazilian Society of Urology 2013, 39(5):614-621.
38. Youssef RF, Shariat SF, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F et al: Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy. Urologic oncology 2013, 31(5):676-681.
39. Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, Lotan Y, Margulis V: Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival. Urologic oncology 2014, 32(1):30.e23-38.
40. Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, Bhat D, Lotan Y: What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urologic oncology 2014, 32(2):128-134.
41. Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, Lotan Y, Margulis V: Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU international 2014, 113(4):668-673.
42. Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M et al: Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. The Journal of urology 2014, 191(1):28-34.
43. Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF, Bolenz C, Sagalowsky AI, Raj GV, Shariat SF et al: Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology? The Journal of urology 2014, 191(4):926-931.
44. Kuntz NJ, Neisius A, Astroza GM, Tsivian M, Iqbal MW, Youssef R, Ferrandino MN, Preminger GM, Lipkin ME: Does body mass index impact the outcomes of tubeless percutaneous nephrolithotomy? BJU international 2014, 114(3):404-411.
45. Rausch S, Lotan Y, Youssef RF: Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: a contemporary review with focus on nonbilharzial squamous cell carcinoma. Urologic oncology 2014, 32(1):32.e11-36.
46. Youssef RF, Neisius A, Goldsmith ZG, Ghaffar M, Tsivian M, Shin RH, Cabrera F, Ferrandino MN, Scales CD, Preminger GM et al: Clinical outcomes after ureteroscopic lithotripsy in patients who initially presented with urosepsis: matched pair comparison with elective ureteroscopy. Journal of endourology 2014, 28(12):1439-1443.
47. Gayed BA, Bagrodia A, Gaitonde M, Krabbe LM, Meissner M, Kapur P, Youssef RF, Sagalowsky A, Lotan Y, Margulis V: Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results. Urologic oncology 2015, 33(1):18.e21-16.
48. Singla N, Gayed BA, Bagrodia A, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O et al: Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. Urologic oncology 2015, 33(6):268.e261-267.
49. Spradling K, Khoyilar C, Abedi G, Okhunov Z, Wikenheiser J, Yoon R, Huang J, Youssef RF, Ghoniem G, Landman J: Redefining the Autonomic Nerve Distribution of the Bladder Using 3-Dimensional Image Reconstruction. The Journal of urology 2015, 194(6):1661-1667.
50. Spradling K, Uribe B, Okhunov Z, Hofmann M, Del Junco M, Hwang C, Gruber C, Youssef RF, Landman J: Evaluation of Ignition and Burn Risk Associated with Contemporary Fiberoptic and Distal Sensor Endoscopic Technology. Journal of endourology 2015, 29(9):1076-1082.
51. Youssef RF, Kapur P, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y: Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target. Urologic oncology 2015, 33(3):111.e111-117.
52. Youssef RF, Krabbe LM, Shariat SF, Lotan Y, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F et al: TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World journal of urology 2015, 33(12):1965-1972.
53. Youssef RF, Spradling K, Yoon R, Dolan B, Chamberlin J, Okhunov Z, Clayman R, Landman J: Applications of three-dimensional printing technology in urological practice. BJU international 2015, 116(5):697-702.
54. Youssef RF, von Rundstedt FC, Kapur P, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y: Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma. The Journal of urology 2015, 193(2):451-456.
55. Cabrera FJ, Kaplan AG, Youssef RF, Tsivian M, Shin RH, Scales CD, Preminger GM, Lipkin ME: Digital Tomosynthesis: A Viable Alternative to Noncontrast Computed Tomography for the Follow-Up of Nephrolithiasis? Journal of endourology 2016, 30(4):366-370.
56. Degener S, Mata DA, Youssef R, Godde D, Tandogdu Z, Roth S, von Rundstedt FC: A review of molecular predictors of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Mini reviews in medicinal chemistry 2016.
57. Dutta R, Abdelhalim A, Martin JW, Vernez SL, Faltas B, Lotan Y, Youssef RF: Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urologic oncology 2016.
58. Dutta R, Okhunov Z, Vernez SL, Kaler K, Gulati AT, Youssef RF, Nelson K, Lotan Y, Landman J: Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses. Journal of endourology 2016, 30 Suppl 1:S28-33.
59. Gayed BA, Youssef R, Darwish O, Kapur P, Bagrodia A, Brugarolas J, Raj G, DiMaio JM, Sagalowsky A, Margulis V: Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned. BMC urology 2016, 16(1):43.
60. Iqbal MW, Shin RH, Youssef RF, Kaplan AG, Cabrera FJ, Hanna J, Scales CD, Jr., Ferrandino MN, Preminger GM, Lipkin ME: Should metabolic evaluation be performed in patients with struvite stones? Urolithiasis 2016.
61. Iqbal MW, Youssef RF, Neisius A, Kuntz N, Hanna J, Ferrandino MN, Preminger GM, Lipkin ME: Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome. Journal of endourology 2016, 30(7):771-777.
62. Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, Pollak M et al: High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with approximately 240-Fold Higher Drug Concentration in Urine than Serum. Molecular cancer therapeutics 2016, 15(3):430-438.
63. Martin JW, Carballido EM, Ahmed A, Farhan B, Dutta R, Smith C, Youssef RF: Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab journal of urology 2016, 14(3):183-191.
64. Okhunov Z, Chamberlin J, Moreira DM, George A, Babaian K, Shah P, Youssef R, Kaler KS, Lobko, II, Kavoussi L et al: Salvage Percutaneous Cryoablation for Locally Recurrent Renal-Cell Carcinoma After Primary Cryoablation. Journal of endourology 2016, 30(6):632-637.
65. Okhunov Z, Moreira DM, Del Junco M, Abedi G, Lobko I, Kaler K, Nguyen ND, Youssef RF, Uchio E, Kavoussi LR et al: Predictors of Complications after Percutaneous Image-Guided Renal Cryoablation for T1a Renal Cortical Neoplasms. Journal of endourology 2016.
66. Shin RH, Cabrera FJ, Nguyen G, Wang C, Youssef RF, Scales CD, Ferrandino MN, Preminger GM, Yoshizumi TT, Lipkin ME: Radiation Dosimetry for Ureteroscopy Patients: A Phantom Study Comparing the Standard and Obese Patient Models. Journal of endourology 2016, 30(1):57-62.
67. Spradling K, Lotan Y, Shokeir A, Abol-Enein H, Mosbah A, Morgan JB, Ghoneim M, Youssef RF: Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder. Urologic oncology 2016, 34(9):417.e411-418.
68. Spradling K, Vernez SL, Khoyliar C, Morgan JB, Okhunov Z, Preminger GM, Lipkin ME, Landman J, Youssef RF: Prevalence of Hyperoxaluria in Urinary Stone Formers: Chronological and Geographical Trends and a Literature Review. Journal of endourology 2016, 30(4):469-475.
69. Spradling K, Youssef RF: Controversies Related to Diabetes and Risk of Bladder Cancer. Mini reviews in medicinal chemistry 2016.
70. Haddad, A. Q., Luo, J.-H., Krabbe, L.-M., Darwish, O., Gayed, B., Youssef, R., Kapur, P., Rakheja, D., Lotan, Y., Sagalowsky, A. and Margulis, V. (2017), Prognostic Value of Tissue Based Biomarker Signature in Clear Cell Renal Cell Carcinoma. BJU Int. Accepted Author Manuscript. doi:10.1111/bju.13776
Grants
1. Grant from Egyptian Cultural & Educational Bureau in Washington, DC (2008-2010): Prognostic biomarkers for bladder cancer. Principal investgator
2. Grant from American Urological Association (Summer Medical Student Fellowship Program): prognostic role of mTOR pathway biomarkers in bladder cancer. Principal investgator
3. Grant from NIH (ICTS Voucher at UCI 2016-2017) Creation of Validated Prognostic Panel of Biomarkers for Squamous Cell Carcinoma of the bladder. Principal investgator
4. Grant from Merck (2016- ongoing): Phase I trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas. Co- Investigator
5. Grant from Deans Summer Research Stipend at UCI (2016): Prognostic role of bladder cancer biomarkers. Principal investigoator
Professional Societies
1. American Urological Association (AUA).
2. Society of Urologic Oncology (SUO).
3. Young urologic oncologists (YUO)
4. Society of Endourology (SEU)
5. Young Endourology (YEU)
6. Egyptian Urological Association
7. Orange County Urological Society (OCUS)
8. Western Section American Urological Association (WSAUA)
9. SWOG Cancer Research Network (SWOG)
10. Chao Family Comprehensive Cancer Center (CFCCC)
Other Experience
Society of Urologic Oncology Clinical Fellow in Urology Department
University of Texas Southwestern Medical Center, Dallas, Tx 2010—2012
University of Texas Southwestern Medical Center, Dallas, Tx 2010—2012
Stone Disease/Endourlogy/Laparoscopy/
Duke University Medical Center 2012—2014
Duke University Medical Center 2012—2014
Graduate Programs
Urology
Research Centers
https://www.ncbi.nlm.nih.gov/pubmed/?term=Youssef+RF
Link to this profile
https://faculty.uci.edu/profile/?facultyId=6331
https://faculty.uci.edu/profile/?facultyId=6331
Last updated
10/07/2020
10/07/2020